ADC Therapeutics SA (ADCT)
NYSE: ADCT
· Real-Time Price · USD
3.35
-0.24 (-6.69%)
At close: Jun 04, 2025, 3:59 PM
3.38
0.71%
After-hours: Jun 04, 2025, 04:36 PM EDT
-6.69% (1D)
| Bid | 3.14 |
| Market Cap | 332.74M |
| Revenue (ttm) | 70.19M |
| Net Income (ttm) | -149.84M |
| EPS (ttm) | -1.42 |
| PE Ratio (ttm) | -2.36 |
| Forward PE | -2.54 |
| Analyst | Buy |
| Ask | 3.5 |
| Volume | 751,988 |
| Avg. Volume (20D) | 489,960 |
| Open | 3.52 |
| Previous Close | 3.59 |
| Day's Range | 3.28 - 3.54 |
| 52-Week Range | 1.05 - 4.13 |
| Beta | 1.96 |
About ADCT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ADCT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ADCT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+37.12%
ADC Therapeutics shares are trading higher after t...
Unlock content with
Pro Subscription
1 month ago
+9.77%
ADC Therapeutics shares are trading higher after the company announced data from preclinical studies of three exatecan-based antibody drug conjugates targeting Claudin-6, prostate-specific membrane antigen and Alanine, Serine, Cysteine Transporter 2
1 month ago · https://www.marketscreener.com
Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer TreatmentThe global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031-a growth story driven not just by rising demand but by genuine innovation. After years of i...
